throbber
J. Pharm. Pharmacol. 1996, 48:136-146
`Received April 21, 1995
`Accepted April 28, 1995
`The Blood-brain Barrier: Principles for Targeting Peptides
`and Drugs to the Central Nervous System
`
`0 1996 J. Pharm. Pharmacol.
`
`DAVID J . B E G L E Y
`Biomedical Sciences Division, King’s College London, Strand, London WC2R 2LS, UK
`
`Abstract
`The presence of the blood-brain barrier (BBB), reduces the brain uptake of many drugs, peptides and other
`solutes from blood. Strategies for increasing the uptake of drugs and peptide-based drugs include;
`structural modifications to increase plasma half-life; improving passive penetration of the BBB by
`increasing the lipophilicity of the molecule; designing drugs which react with transporters present in the
`BBB; and reducing turnover and efflux from the central nervous system (CNS).
`
`Introduction
`The blood-brain barrier (BBB) is a vital element in the
`regulation of the constancy of the internal environment of
`the brain. The composition of the extracellular fluid of the
`brain is controlled within very precise limits, largely inde-
`pendently of the composition of the circulating blood, to
`provide a stable environment in which the integrative neu-
`ronal functions of the brain can optimally take place. The
`blood-brain barrier is formed at the level of the endothelial
`cells of the cerebral capillaries. These cells are characterised
`by having
`tight continuous circumferential junctions
`between the cells of the capillaries thus abolishing any
`aqueous paracellular pathways between
`the
`cells
`(Brightman 1992). The endothelium is thus characterised
`by exhibiting a high transendothelial electrical resistance in
`the region of 1500-20000 cm2 (Butt et a1 1990). The
`presence of the tight junctions and the lack of aqueous
`pathways between cells greatly restricts the movement of
`polar solutes across the cerebral endothelium.
`Some regions within the central nervous system (CNS)
`lack a BBB and the capillaries are fenestrated allowing the
`free movement of solutes between the blood and the sur-
`rounding interstitial fluid. These areas are collectively
`termed the circumventricular organs (CVOs) and comprise
`the choroid plexus, the median eminence, the neurohypo-
`physis, the pineal gland, the organum vasculosum of the
`lamina terminalis, the subfornical organ, the subcommisural
`organ and the area postrema. Some of these structures, the
`median eminence, the neurohypophysis and the pineal are
`neurohaemal organs specialised for the release of neuroen-
`docrine secretion into the bloodstream. The other areas may
`be regarded as windows of the brain where a limited number
`of neurones within the immediate vicinity of the circumven-
`tricular organ have an unrestricted access to blood solutes.
`This access enables the brain to monitor closely the compo-
`sition of the blood and to react accordingly. The ependymal
`cells surrounding the circumventricular organs have what
`appear to be tight junctions between them presumably to
`enclose a volume of brain extracellular fluid (ECF) sur-
`rounding the CVO to prevent diffusion of interstitial solutes
`away from the region of the circumventricular organ
`
`(Brightman 1992). The relative surface area of the perme-
`able fenestrated capillaries of the circumventricular organs
`compared to the tight BBB capillaries is 1 : 5000. Given these
`considerations there is little possibility of these high perme-
`ability areas being able to influence the composition of the
`bulk of the brain extracellular fluid and the CVOs do not
`form a realistic route for drug entry into the brain.
`The presence of the BBB is easily demonstrated by study-
`ing the distribution of the inert hydrophilic marker inulin
`(Begley 1992a, 1994) (Table I). The percentage distribution
`spaces in brain regions with a BBB correspond to the plasma
`volume of the brain area. In the choroid plexus and the
`anterior and posterior pituitary where the capillaries are
`fenestrated the inulin space corresponds to the extracellular
`space of the tissue.
`Because of the presence of the BBB a number of specific
`transport mechanisms are required to be present in the
`cerebral endothelial cells to ensure that the brain receives
`an adequate supply of nutrients. These are illustrated and
`described in Fig. 1.
`Passive diffusion may occur across the endothelium,
`either through the cells themselves or through the tight
`junctions between cells. Movement across the BBB by
`passive mechanisms will be determined by considerations
`such as molecular weight and lipophilicity as discussed later.
`The entry of glucose into the brain is via a facilitated carrier
`GLUT-1 present in the endothelial cells. GLUT-1 is insulin
`insensitive and always shows a relatively high level of
`expression. It will however upregulate in chronic hypo-
`glycaemia and downregulate in chronic hyperglycaemia.
`Amino acids are transported across the BBB on a variety
`of transporters. Large neutral amino acids, such as tyrosine,
`phenylalanine, leucine, isoleucine, valine, histidine and
`methionine are transported into the brain by an energy-
`dependent transporter termed system-L which is present on
`the luminal and abluminal membranes and is principally
`directed from blood to endothelial cell and from endothelial
`cell into brain. System-ASC which transports as model
`substrates alanine, serine and cystine, plus a number of
`neutral amino acids such as threonine and asparagine is
`also expressed
`to a lesser extent and with the same
`directional properties as system-L. There is an obvious
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1031 - Page 1
`
`

`
`Table 1. Percent inulin spaces in various regions of the guinea-pig
`brain determined 10 min after intravenous bolus injection.
`
`Capillary lumen
`
`Brain ECF
`
`TARGETING PEPTIDES AND DRUGS TO THE CNS
`
`137
`
`Diffusion
`
`GLUT ,
`
`System L,
`
`System A X
`
`Receptors
`(h)
`
`Brain region
`
`Whole brain
`Olfactory bulb
`Hippocampus
`Caudate nucleus
`parietal cortex
`Hypothalamus
`Choroid plexus
`pituitary (anterior & posterior)
`
`Inulin space (YO)
`1.77 f 0.14
`2.30 f 0.37
`1.45 f 0.22
`1.26 f 0.18
`2.45 f 0.30
`20.80 f 1.10
`
`1.50 * 0.18
`26.70 * 2.90
`
`The differences between brain area possessing a blood-brain
`barrier and areas where the capillaries are fenestrated may be
`illustrated by injecting experimental animals with radiolabelled
`inulin (5000 Da). Where there is a blood-brain barrier the inulin
`occupies the plasma space of the tissue which is between 2.45 and
`1.26% depending on the region. Where the capillaries are fene-
`strated the inulin occupies the plasma and the extracellular space of
`the tissue giving spaces of approximately 25%. The inulin spaces
`were determined after an intravenous bolus injection of 5OmCi
`[3H]inulin in anaesthetised guinea-pigs. After 10 min, blood samples
`were taken by cardiac puncture and the animals were decapitated.
`Brain samples were then dissected out and the inulin space calcu-
`x 100. Mean f s.e.m.
`lated as: inulin space = Cplasma/Chrdln
`
`+ & - S y s t e m A
`
`overlap in the substrates acceptable to system-L and ASC.
`System-A, transporting principally glycine and proline is
`present on the abluminal membrane of the endothelial cells
`and is directed out of the brain (Betz & Goldstein 1978). A
`transporter for the dicarboxylic amino acids, glutamic and
`aspartic acid, is also present in the BBB and is directed out
`of the brain. Both system-A and system-ASC are sodium- as
`well as energy-dependent. A number of specific receptors for
`solutes also exists both on the luminal and abluminal
`surfaces of the endothelial cells. These receptors may be
`linked to second messengers such as CAMP or may mod-
`ulate the activity of channels or transporters in the BBB.
`There may also be transporters in the cell membrane for
`solutes such as small peptides.
`The level of endocytic activity in the BBB, compared with
`other endothelia, is minimal. However transcytosis for
`certain macromolecules may occur and form a low capacity
`transport mechanism for these solutes. Receptor-mediated
`endocytosis may be solute-specific and inducible by that
`solute.
`The BBB also has a physiological and biochemical dimen-
`sion in that the endothelial cells have a high density of
`mitochondria compared with other endothelia presumably
`reflecting a high level of oxidative ATP production. In
`addition the BBB is the site of a high level of enzyme activity
`directed towards the inactivation of centrally active blood-
`borne solutes and toxins (Audus et a1 1992; Grieg 1992). The
`high enzyme activities present in or on the cerebral endothe-
`ha1 cells include monoamine oxidase (MAO) types A and B,
`L-amino acid decarboxylase (AAD), catechol-0-methyl
`transferase (COMT), butyryl-cholinesterase (BChE) and 4-
`aminobutyrate aminotransferase. Levels of gamma-gluta-
`my1 transpeptidase activity are high in cerebral endothelial
`cells and are thought to be related to amino acid transport
`phenomena. Also membrane-bound epoxidehydrolase
`(mEH), UDP-glucuronosyl-transferase (UGT), benzoxyre-
`sorufin-0-de-ethylase, NADPH cytochrome P450 reductase
`
`FIG. I. Interactions of solutes with the blood-brain barrier. Solutes
`both in blood and in the brain extracellular fluid may interact with
`the BBB in a variety of ways. Solute which traverse the BBB by
`diffusion may either diffuse to a limited extent through the zona
`occludens (a) or directly across the endothelium (b). Polar solutes,
`for example glucose, employ a facilitated carrier Glut-I (c), in the
`cell membrane and neutral amino acids employ Systems-L and ASC
`(d and e). Glut-1, system-L and System ASC are represented in the
`same orientation in both the luminal and the abluminal membranes
`of the cerebral capillary endothelial cells. System-A (f) transports
`glycine and a system for the acidic amino acids (g) transports
`glutamic acid and aspartic acid from the brain extracellular fluid
`into the cerebral endothelial cells. There are also receptors for
`blood-borne solutes on the luminal surface of the endothelium
`(i and h). These receptors may be linked to intracellular messengers
`or control the activity of other channels in the luminal membrane
`and thus alter the activity of the endothelial cells. Specific peptide
`transporters have been demonstrated in the luminal endothelial
`membrane fj) transporting peptides into the endothelium. If these
`peptides are to reach the brain extracellular fluid by this route there
`must be equivalent transporters in the abluminal membrane. Larger
`peptides and proteins will be internalized by an endocytic mechan-
`ism (k). This may be receptor-mediated or non-specific in nature.
`The level of endocytic activity in the cerebral capillary endothelium
`is much lower than in other tissues endothelia and transcytosis
`remains a controversial topic. Multidrug resistance protein or
`P-glycoprotein is expressed constitutively in the luminal membrane
`of the cerebral endothelial cells (I) and transports a variety of
`structurally unrelated substrates out of the endothelium. Many of
`these are lipophilic and potentially neurotoxic and would otherwise
`enter the brain to a greater extent.
`
`and glutathione-S-transferase activities are high in brain
`microvessel preparations and in the choroid plexus. These
`enzymes are thought to play a part in the metabolism of
`drugs and xenobiotic compounds.
`The intrinsic membrane protein P-glycoprotein some-
`times referred to as multidrug resistance protein (mdr-
`protein) is also present in the luminal plasma membrane
`of the endothelial cells constituting blood-brain barrier.
`This is an efflux pump which appears to be a constituent
`part of the BBB and transports a wide range of structurally
`unrelated substances out of cells. Pgp is an ATP-dependent
`pump and is a member of a family of intrinsic membrane
`proteins which are normally expressed at the BBB, the
`intestine, the liver and the kidney (Cordon-Cardo et a1
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1031 - Page 2
`
`

`
`138
`
`DAVID .I. BEGLEY
`
`/
`/
`/
`,*r BCNU
`
`CCNU
`
`Vinbbstine
`
`Vincristine
`
`/' Epipodophyllotoxin
`,/. Sucrose
`8 1
`
`-4
`
`L
`-3
`
`I
`
`1
`
`I
`
`2
`
`I
`
`3
`
`I
`I
`0
`-2
`-1
`1
`Log octanollwater partition coefficient
`FIG. 2. The relationship of the octanol/water partition coefficient to blood-brain barrier permeability for some selected
`drugs. Substances falling on the dotted line would have a direct relationship between their brain uptake and their lipid
`solubility. Note that there is a wide scatter of points around the line. Vinblastine and vincristine are known substrates for
`the efflux pump P-glycoprotein expressed at the blood brain barrier and this limits their penetration into brain. Other
`substances which also lie well away from the line but are not shown on the plot are those which have carrier-mediated
`uptake mechanisms such as glucose and amino acids, which are fairly polar with partition coefficients between I x lo-'
`but with high BBB permeabilities.
`and I x
`BCNU = I .3-bis-chloro(2-chloroethyl)-l-nitrosourea; CCNU = I-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea; PCNU =
`1 -(2-chloroethyl)3-(2,6,-dioxo-3-piperidyl)-nitrosourea; 5FU = 5-fluorouracil. Adapted from Greig (1992).
`
`1989; Ruez & Gros 1994). The role of Pgp therefore appears
`to be a protective one transporting a range of potentially
`toxic substances out of the body. The expression of Pgp
`occurs in many tissues including malignant tissue after
`exposure to cytotoxic drugs where it confers resistance to
`a wide range of cytotoxic agents. Hence its alternative name
`multidrug resistance protein. In this situation its acts to
`maintain the intracellular levels of cytotoxic drugs below a
`toxic level and thus frustrates repeated cancer chemother-
`apy. Its constitutive role in the normal BBB is inferred to be
`a protective one reducing the entry of lipophilic and neuro-
`toxic substances into the CNS.
`
`Improving passive permeation of the BBB
`For many drugs that enter the brain by passive diffusion
`their brain-uptake and lipid solubility are well correlated
`(Fig. 2). Lipid solubility is most often determined as a
`partition coefficient between buffer and octanol and is
`quoted as the logarithm of the partition, logPo,,. Many
`small solutes entering the brain do so by dissolving in the
`lipid of the cell membrane. In-vitro studies using cultured
`cerebral endothelial cells have suggested that in this system
`the relationship between lipid solubility and brain uptake
`might be a sigmoidal one (Oldendorf 1974; Van Bree et a1
`1988). With substances having a logP between -2.00 and 0
`(partition coefficients of 0.01 and 1.00) lying on the more
`linear portion of the curve. Very hydrophobic substances
`show little further increase in brain uptake and hydrophilic
`substances which are polar and highly ionized at physio-
`logical p H also have a limited brain uptake.
`
`It has been suggested by Levin (1980) that large lipid-
`soluble substances with a molecular weight above 500Da
`become physically impeded from crossing the cell membrane
`and thus exhibit a molecular weight cut-off. This has been
`used to explain the low brain-uptake of substances such as
`vinblastine, vincristine and cyclosporin, which lie well off
`the regression line suggested in Fig. 2. However it is now
`well-established that these cytotoxic agents are substrates of
`P-glycoprotein (Tsuji et al 1992, 1993) which is actively
`extruding them from the cerebral endothelial cells. Surpris-
`ingly an increase in molecular volume may actually enhance
`brain uptake (Abraham et a1 1994).
`It has been suggested that delta logP, defined as the
`logPoctanol/bul€er minus the logPcyclohexane/huffer is a better pre-
`dictor of brain uptake (Young et al 1988). Delta logP reflects
`the hydrogen-bonding capacity of a substance and this prop-
`erty in turn influences brain uptake. In general in a series of
`related substances those with a lower-hydrogen bonding
`potential enter the brain the most readily. The hydrogen-
`bonding potential determines the activation energy necessary
`to pluck a molecule out of the aqueous phase and into the lipid
`phase of a membrane. Various physical factors influencing
`brain uptake have been incorporated into a predictive equa-
`tion for brain uptake (Abraham et al 1994).
`To maximize the brain uptake and the bioavailability of a
`substance to the brain a number of molecular manipulations
`may be carried out to alter the properties of a substance;
`these may be summarized as:
`1. Increasing the plasma stability and hence plasma half life.
`2. Improving lipid solubility.
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1031 - Page 3
`
`

`
`(a) pyroglutamyl-histidyl-prolinamide
`WH)
`
`R I = H , R 2 = H
`
`(b) pyroglutamyl-histidyl-3 methylprolinamide
`(Pyr-His-MepNH2. RX 74355)
`R l = H , R Z = C H ,
`
`(c) pyroglutamyl-histidy1-3,3 dimethylprolinamide
`(Pyr-His-Dmp-NH2. RX 77368)
`R1= CH,. R2 = CH,
`
`139
`TARGETING PEPTIDES AND DRUGS TO THE CNS
`(Table 2). The central nervous activity of the T R H
`analogues is also enhanced (Brewster et al 1981; Brewster
`1983), possibly as the result of increased brain penetration
`although an enhanced central potency should also be
`considered.
`Other simple modifications to peptides that may be made
`are to amidate the C-terminus and acetylate the N-terminus
`both of which confer an increased resistance to exopepti-
`dases. In addition acetylation of the N-terminus also
`increases lipid solubility significantly.
`An excellent example of increasing brain uptake by
`enhancing lipid solubility and reducing hydrogen bonding
`capacity is the chemical conversion of morphine to heroin
`(diacetyl-morphine). Substitution of the two hydroxyl
`groups of morphine by acetyl groups in heroin increases
`the brain uptake over twenty-fivefold (Oldendorf 1974). As
`a general rule for each pair of hydrogen bonds removed
`from a molecule there is a log order increase in BBB
`permeabilty. Once within the brain, heroin is rapidly con-
`verted to monoacetyl morphine and more slowly to mor-
`phine. Thus the rapid brain entry of heroin in comparison
`with morphine makes it a favoured drug of abuse and
`presumably enhances its addictive potential.
`In the case of many peptides the introduction of
`D-isomers of the naturally occurring amino acids in to the
`peptide sequence can greatly enhance the plasma half life of
`the peptide. Again the reactivity with plasma peptidases is
`greatly reduced. For example octreotide (D-Phe-Cys-Phe-
`D-Tyr-Lys-Thr-Cys-Thr-OH : sandostatin : SMS 20 1-995)
`is an octapeptide analogue of somatostatin Ala-Gly Cys-
`Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH).
`The
`attenuated peptide with the D substitutions, D-Phe at
`position two of somatostatin and D-Trp at position five,
`extends the first order half-life of somatostatin from 2-3 min
`in human plasma to 113 min (Lamberts 1987). The substitu-
`tion of D-Phe at position four also increases the growth
`hormone inhibiting potency of sandostatin compared with
`somatostatin by some 45 times. D-Amino acid substitutions
`also have marked effects on the plasma half-lives of
`encephalin analogues. Examples are two analogues of
`leucine encephalin (Tyr-Gly-Gly-Phe-Leu), namely DADLE
`
`FIG. 3. Structure of T R H and related analogues RX 74355 and
`RX 77368. The substitution of the methyl groups into the proline
`residue increases the plasma half-lives and the central effectiveness
`of the molecules.
`
`3. Enhancing or maintaining reactivity with existing BBB
`transport mechanisms.
`4. Retaining central nervous activity.
`5. Increasing the stability in brain extracellular fluid and
`reducing reactivity with efflux transport mechanisms in the
`CNS.
`
`A number of chemical modifications can be carried out to
`improve the CNS activity of drugs. For example the peptide
`thyrotropin
`releasing hormone
`(TRH-pyroglutamyl-
`histidyl-prolinamide) has a short plasma half life due to
`circulating peptidases. To extend the half-life, methyl
`groups may be added to the prolinamide residue to produce
`a 3-methylprolinamide (RX74355) and a 3,3-dimethylproli-
`namide (RX77368) (Brewster et a1 1981, 1983) (Fig. 3).
`These methyl substitutions increase the lipid solubility of
`the molecule and also the molecular volume. The substitu-
`tions also increase the first order half-lives in human plasma
`from 33 (TRH) to 210 (RX74355) and 1080min (RX77368)
`
`Table 2. First-order half-lives (min) of TRH, RX74355, and RX77368. There are
`significant species differences in the rates at which plasma and a brain homogenate
`will break down T R H and its analogues.
`
`T R H
`
`RX74355
`(Methylproline)
`
`RX77368
`(Dimethylproline)
`
`Rat
`Plasma
`Brain homogenate
`Dog
`Plasma
`Brain homogenate
`Man
`Plasma
`Brain homogenate
`Mouse
`Plasma
`Brain homogenate
`
`22
`9
`
`> 1500
`11
`
`33
`18
`
`215
`12
`
`From Brewster (1983).
`
`I I4
`54
`
`> 1500
`90
`
`210
`66
`
`> 1500
`28
`
`390
`190
`
`> 1500
`174
`
`1080
`168
`
`> 1500
`150
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1031 - Page 4
`
`

`
`140
`
`DAVID J. BEGLEY
`
`Ala-Gly-Cvs-Lvs-Asn-Phe-Phe-Tm-Lvs-Thr-Phe-Thr-Ser-Cvs-OH
`Somatostatin14
`
`D-Phe-Cvs-Phe-D-Tm-Lvs-Thr-Cvs-Thr-OH
`
`Ac-D-Phe-Cvs-Tvr-D-T~-Lvs-Val-Cvs-Thr-NH2
`
`0.23'
`
`D-Phe-CvsTvr-D-Tm-Lvs-Val-Cvs-TrpNHz
`
`RC160
`
`0 ,092'
`
`D-Phe-Cvs-Tvr-D-T~-Lvs-Val-Cvs-Thr-NHz
`
`RC121
`
`r
`0
`
`1
`0.05
`
`I
`0.1
`
`I
`0.15
`
`I
`0.2
`
`I
`0.25
`
`Unidirectional cerebrovascular
`influx constant
`(pL g-' min-1)
`FIG. 4. Unidirectional cerebrovascular permeability constants (K,") of some somatostatin analogues. The brain uptakes
`are determined by intravenous bolus injection techniques. The structure of the analogues is given with that of
`somatostatin for comparison. Unfortunately the brain uptake of somatostatin cannot be determined by a comparable
`method as it is very unstable in plasma. Data from Begley et al (1992b) and Banks et al (1990).
`
`(D-Ala2, D-Leu5-encephalin) and dalargin (Tyr-D-Ala-Gly-
`Phe-Leu-Arg) both of which have greatly extended half-lives
`in plasma compared with the parent peptide.
`A number of somatostatin analogues exist where the
`plasma half-life is extended and the lipid solubility is altered
`thus modifying two factors which influence brain uptake,
`plasma half life and biological potency of the molecules.
`Intravenous bolus injection studies have been carried out to
`measure the brain uptake of these peptides, (Banks et al
`1990; Begley 1992b, 1994). These somatostatin analogues
`are amphiphilic and their brain uptakes are non-saturable
`suggesting that their penetration into the brain will be
`passive. However changes in the molecular structure of the
`analogues produce significant changes in brain uptake. Fig. 4
`illustrates the brain uptakes of four octapeptide analogues
`of somatostatin, determined by an intravenous bolus injec-
`tion technique (Banks et al 1990; Begley 1992b, 1994) which
`have D-Phe and D-Trp substitutions in the molecule. Com-
`pared with RC 121 the substitution of a Trp residue at
`position 8 compared with RC 160, thus introducing an
`_ _
`additional aromatic side chain into the molecule, approxi-
`mately doubles
`the cerebrovascular permeability constant.
`Acetylating the
`N-terminus of RC 121 as in RC 161, and
`
`therefore increasing the lipid solubility, increases the perme-
`ability constant almost sixfold. The peptide RC 160 has
`marked and prolonged analgesic actions after intravenous
`administration (Eschalier et a1 1990).
`Using synthetic peptide sequences which have hydropho-
`bic properties may provide a mechanism for inserting a
`peptide into the cell membrane (Begley 1994). For example a
`number of naturally-occurring peptides have hydrophobic
`regions which demonstrate a natural affinity for cell mem-
`branes. Mellitin, a component of bee venom (Kaiser &
`Kezdy 1987), is a 26-amino acid peptide (Fig. 5). The N-
`terminal amino acids 1-20 contain two a-helical regions
`1-10 and 13-20 which are hydrophobic and insert the
`molecule into the cell membrane, the lysine residues 21 -26
`are highly cationic and are thought to open up pores thus
`permeabilizing the membrane (Kaiser & Kezdy 1987).
`Signal peptides are similar hydrophobic regions in a pre-
`pro-peptide or protein which enable the entire molecule to
`be inserted through the unit membrane of the endoplasmic
`reticulum. The signal amino acid sequence is not conserved
`between pre-pro-proteins and thus the common feature is
`the hydrophobicity (lipohilicity) of the region (Engelman &
`Steitz 1981; Emr & Silhavey 1983; Begley 1994). The
`
`5
`10
`N- ly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr Thr-Gly
`+
`
`15
`
`25
`IlleSerTrpllejLys- Arg-Lys- Arg-Gl~-Gln NH2
`+ + + +
`FIG. 5. Amino acid sequence of mellitin. The hydrophobic areas which insert into the cell membrane are boxed
`Positively-charged side chains which disrupt the cell membrane are indicated with + .
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1031 - Page 5
`
`

`
`TARGETING PEPTIDES AND DRUGS TO THE CNS
`
`141
`
`230 nm
`
`I
`
`I
`
`\
`Poly-butyl-cyanuacrylate nanoparticle
`
`FIG. 6. Schematic diagram of a nanoparticle. The dalargin is
`absorbed onto the surface of the nanoparticle which is then
`coated with polysorbate-SO.
`
`function of the signal sequence is thus to enable a large polar
`protein or peptide to traverse a unit membrane without
`damage to either the pre-pro-protein or the membrane.
`Indeed passive permeation of the BBB may not be limited
`to small molecules. Colloidal polymer particles (nanoparti-
`cles) may be formed from poly(butylcyanoacrylate) with an
`average diameter of 230 nm. Nanoparticles have been used
`to deliver the peptide dalargin to the CNS (Fig. 6) (Engel-
`man & Steitz 1981; Emr & Silhavey 1983; Kreuter et al
`1995). Dalargin is a hexapeptide analogue of encephalin
`which is stable in plasma but has little central analgesic
`action when injected intravenously. If dalargin is absorbed
`onto the surface of nanoparticles and these particles are then
`coated with the detergent polysorbate-80 and the complex
`injected into mice, a pronounced analgesic effect is obtained
`reaching a maximum in 45min (Fig. 7). Little effect is
`produced with dalargin, nanoparticles or polysorbate-80
`alone. The effect is also dose-dependent with a greater
`absorption of dalargin onto the particles and is reversible
`by naloxone (Engelman & Steitz 198 1; Emr & Silhavey 1983;
`Kreuter et al 1995). Presumably the detergent enables the
`particles to penetrate the BBB and the dalargin is released
`from the nanoparticles in effective amounts within the brain.
`In contrast, attempts to use liposomes to deliver drugs to the
`brain have been universally unsucessful (Pardridge 199 1).
`
`0
`
`15
`
`30
`
`45
`
`60
`
`75
`
`90
`
`Time (min)
`FIG. 7. Analgesia in mice produced by dalargin-loaded nanoparti-
`cles. Analgesia is expressed as the percent of the maximally possible
`effect after intravenous injection of the indicated dose. (n = 6,
`mean
`s.d.)
`
`Exploiting existing transporters
`As mentioned earlier the presence of a blood-brain barrier
`to polar molecules dictates that a number of transporters
`must be present in the cerebral endothelium in order to
`supply the brain with an adequate supply of nutrients. The
`kinetic properties of some of these transporters are shown in
`Table 3.
`The glucose carrier GLUT-I has a very large capacity to
`transport ,BD-glucose across the BBB. The intestinal Na ' 1
`D-glucose transporter will also transport /3-glycosides but
`not as effectively as the preferred substrate glucose. Given
`that GLUT-] and the intestinal transporter have a similar
`
`Table 3. Kinetic values for some transport systems present at the BBB.
`
`Representative substrate
`
`Transporter
`
`Glucose
`Lactic acid
`Phenylalanine (apparent)
`Phenylalanine (real)
`Arginine (apparent)
`Leucine encephalin
`Arginine vasopressin
`Adenosine
`Adenine
`
`Hexose: Glut- I
`Monocarboxylic acid
`System-LI
`System-L1
`Basic amino acid
`Peptide specific
`Peptide specific
`Nucleoside
`Purine base
`
`K, ( P M )
`11000 f 1400
`1800 f 600
`30.0 f 1.0
`1 1 .o f 2.0
`40.0 f 24
`39.0 f 3.2
`25.0 * 3.0
`2.08 f 0.32
`11.0f3
`
`V,,,
`
`(nmol min-1 g-1)
`1420 f 140
`91 f 3 5
`14.0 f 4.0
`25.0 f 6.0
`5.0 f 3.0
`160.0 f 22.0*
`5.49 f 0.74*
`0.75 f 0.08
`0.5 f 0.09
`
`K, (pL g-' min-I)
`
`44.0 f 14.0
`8.0 f 1.0
`0.062 f 0.086
`0.021 f 0.044
`
`*pmoI min-l g-l.
`The K, value IS the concentration of substrate at which the transporter is half-saturated and indicates the affinity of the substrate for the
`is the maximal transporting capacity of the system. The Glut-1 transporter has a high affinity and a high capacity for
`system. The V,,,
`glucose. As explained in the text many amino acids share a common transport system and will have different affinities (K,)
`for the systems;
`because of this they will compete with each other for transport. Thus an amino acid will have a real K, and V,,, where their kinetic values are
`determined in the absence of competing amino acids and apparent values when competing amino acids are present. The Kd is a measure of the
`Passive diffusional component to the movement of a solute and is significant in the case of the amino acids but is much smaller in the case of
`the more polar peptides. Means f s.e.m. Compiled from various sources.
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1031 - Page 6
`
`

`
`142
`
`DAVID J. BEGLEY
`
`1
`
`2
`
`3
`
`4
`
`5
`
`51
`rsH HSi
`ys-.?
`
`6
`
`7
`
`8
`
`9
`
`H,N-Tyr-Dben-Gly-Phe-Dben-Ser-Gly-&NH,
`D-Gk-p(l-0) _I
`
`0 II
`H,N-Tyr-DPen-Gly-PheDPen-Ser-Gly-C-NH,
`D-GIc-p(I
`
`0 II
`
`r S H H S i
`H2N-Tyr-DCys-Glyr-Phe-DCys-Ser-Gly-C-NH2
`b + P
`
`H d
`
`
`
`r S ---S
`
`1 II
`
`0
`
`H
`
`10
`
`H,N-Tyr-DPen-Gly-Phe-DPen-C-NH,
`
`DPDPE 6
`
`H,N-Tyr-DCys-Ser-Phe-DCys-Gly-C-NH,
`~ - ~ i c - p - ( i -q-J
`
`0
`
`rS-' 1 II
`H,N-Tyr-DCys-Ser-Phe-DCys-Gly-C-NH,
`~ - ~ i c - p - ( i -0) J
`rS-' 1 I1
`0
`H2N-Tyr-LCys-Gly-Phe-LCys-Ser-C-NH,
`D-Gic-p-(i-rO) J
`1 II
`
`0
`r S H HS
`H2N-Tyr-DCys-Gly-Phe-DCys-Ser-Gly-C-NH,
`6 + p
`
`D - G i c - p - ( i a d
`
`rs -' 1 FI
`
`D-Glc-&( 1 4
`
`FIG. 8. Some analogues of DPDPE (D-pen2.' encephalin). DPDPE is a &receptor agonist but is ineffective
`intraperitoneally. Analogues 4 and 5 and 8 and 9 are 6- and preceptor agonists. However only analogues 4 and 5
`produce analgesia determined by the tail flick test after intraperitoneal administration. From Polt et al (1994).
`
`structure it might be possible that peptide-P-D-glycoside
`conjugates may be acceptable to the brain glucose transpor-
`ter (Polt 1994). Some glycopeptides administered intra-
`peritoneally as L-serinyl-P-D-glycoside analogues of Met'
`encephalin (Fig. 8) have been shown to be transported
`across the BBB and bind to p - and 6-opioid receptors in
`the brain. The glycopeptide encephalin analogues 4 and 5
`produce a marked and long-lasting analgesia after intraper-
`itoneal administration as determined by tail-flick and hot-
`plate assays in mice (Fig. 9). This analgesia is reversible with
`naloxone (Polt 1994). It is suggested that GLUT-I is
`responsible for transporting the glycopeptide into the
`CNS. Interestingly, these glycopeptides have a reduced
`lipohilicity compared with the native encephalins but the
`conjugate has reactivity with both the glucose transporter
`
`1 O O r
`
`-
`
`0 6 . '
`w
`20
`0
`
`'
`40
`
`.
`
` ' *
`'
`80
`60
`Time (min)
`
`'
`100
`
`'
`
`120
`
`FIG. 9. Analgesia produced by DPDPE glycopeptide analogue 5.
`Intraperitoneal administration of this pegtide produces dose-related
`and long-lasting antinociception in a 55 C tail-flick test. From Polt
`et al (1994).
`
`and with opioid receptors within the brain (Polt 1994). The
`brain transport appears to be specific for P-0-linked glyco-
`sides as a-linked and N-linked and 0-acyl linked glucose
`conjugates (Fig. 8) d o not appear to cross the BBB and have
`no analgesic effects. Also only glycosides linked via the
`serine residue showed any CNS activity. In this connection
`it is interesting to note that morphine-6-glucuronide formed
`naturally in the liver is 10-50 times more potent in producing
`analgesia than morphine itself and that morphine may act as
`a prodrug with the 6-glucuronide producing a significant
`part of the analgesic effect. There is thus a good possibility
`that glycosylation might be applicable to the delivery of a
`range of drugs across the BBB.
`System-L transporting neutral amino acids into the CNS
`is another obvious target for drug analogues or complexes
`which might have a reactivity with this system. To date, the
`most successful exploitation of system-L is the delivery
`of L-dopa to the bra

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket